Millennium & Copthorne Hotels Share News (MLC)

IN BRIEF: Malin Corp investee signs agreement with Astellas Pharma

Malin Corp PLC - Dublin-based investor in life sciences companies - Investee company Poseida Therapeutics Inc enters into a research collaboration and licensing agreement with Xyphos Biosciences Inc, a wholly owned subsidiary of Astellas Pharma Inc. Says agreement is to develop novel convertibleCAR programs by combining the innovative cell therapy platforms from each of the companies.

UK shareholder meetings calendar - next 7 days

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

TRADING UPDATES: Puma and Puma Alpha invest in Not Another Beer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Malin confirms new executive director joins board

Malin Corp PLC - Dublin-based investor in life sciences companies - Confirms that Fiona Dunlevy joins the board as an executive director. Outgoing Chief Executive Officer Darragh Lyons will resign from the board on December 1. These changes were first announced in July, alongside Chair Liam Daniel undertaking additional responsibilities as executive chair from October 2.

TRADING UPDATES: Solid State sees strong orders in security & defence

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

Malin CEO Darragh Lyons to resign before end of the year

(Alliance News) - Malin Corp PLC said that its Chief Executive Officer Darragh Lyons will resign from his position before the end of 2023, and that Fiona Dunlevy will become executive director effective from October 2.

Malin returns EUR140 million to shareholders through tender offer

(Alliance News) - Malin Corp PLC on Tuesday said it will return EUR140 million to shareholders, through a tender offer.

UK shareholder meetings calendar - next 7 days

UPDATE: Malin confident heading into 2023; proposes investor return

Malin Corp PLC - investor in life sciences companies - Estimated intrinsic equity value per share at December 31 rises 7.4% to EUR9.34, from EUR8.70 a year earlier. Posts 2022 pretax profit of EUR12.3 million, swinging from loss of EUR3.8 million. "We have made significant progress in supporting our assets towards key milestones and value inflection points, which have catalysed value realisation opportunities," Chief Executive Darragh Lyons says. "As we look to the year ahead, we are confident that our investee companies can continue to progress their innovative technologies and clinical programmes with the aim of advancing important therapies for patients and creating significant value for their stakeholders." In addition, plans to return EUR140 million to shareholders at EUR9.30 per share by way of a tender offer.

Malin to return up to EUR140 million to shareholders

(Alliance News) - Malin Corp PLC on Thursday it launched a proposed tender offer and the return of capital of up to EUR140 million to qualifying shareholders.

TRADING UPDATES: CyanConnode to raise funds; Pure Gold cancels listing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

TRADING UPDATES: British Honey launches review; Malin agrees on case

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Malin swings to interim profit as investment income surges, costs cut

(Alliance News) - Malin Corp PLC on Wednesday reported a swing to an interim profit as investment income grew and administrative expenses were slashed.